Skip to Main Content

Otsuka Multi-Tracer/Multi-Dose Study (snd_ro2)

Conditions

Men's Health

Phase I

What is the purpose of this trial?

You are invited to take part in a research study designed to evaluate the action of a new

investigational drug (a drug that has not been approved by the FDA), centanafadine. This drug is

designed to interact with serotonin (SERT), dopamine (DAT), and norepinephrine (NET)

transporters in the brain. A transporter is a protein in the brain that affects brain function. Many

medications are designed to reach and interact with transporters in your brain. Centanafadine is

being studied as a possible treatment for attention-deficit/hyperactivity disorder (ADHD).

 We will be using an imaging technique called PET (Positron Emission Tomography) to

measure the interaction of centanafadine and the transporters in your brain. You will receive up

to 8 oral doses of centanafadine and up to five injections of radiotracer during this study. A

radiotracer is a low dose of a drug that has a radioactive marker attached to it, so that it can be

detected in the brain. The radiotracer gives off energy (gamma-rays) that is detected by the PET scanner to create brain images.

  • Trial with
    Otsuka Pharmaceutical Development & Commercialization, Inc.
  • Start Date
    03/26/2019
  • End Date
    12/30/2019
Trial Image

For more information about this study, contact:

Mark Dias

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/24/2019
  • Study HIC
    #2000023962